Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biomed J ; 43(4): 375-387, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32611537

RESUMO

BACKGROUND: Highly pathogenic emerging and re-emerging viruses continuously threaten lives worldwide. In order to provide prophylactic prevention from the emerging and re-emerging viruses, vaccine is suggested as the most efficient way to prevent individuals from the threat of viral infection. Nonetheless, the highly pathogenic viruses need to be handled in a high level of biosafety containment, which hinders vaccine development. To shorten the timeframe of vaccine development, the pseudovirus system has been widely applied to examine vaccine efficacy or immunogenicity in the emerging and re-emerging viruses. METHODS: We developed pseudovirus systems for emerging SARS coronavirus 2 (SARS-CoV-2) and re-emerging avian influenza virus H5 subtypes which can be handled in the biosafety level 2 facility. Through the generated pseudovirus of SARS-CoV-2 and avian influenza virus H5 subtypes, we successfully established a neutralization assay to quantify the neutralizing activity of antisera against the viruses. RESULTS: The result of re-emerging avian influenza virus H5Nx pseudoviruses provided valuable information for antigenic evolution and immunogenicity analysis in vaccine candidate selection. Together, our study assessed the potency of pseudovirus systems in vaccine efficacy, antigenic analysis, and immunogenicity in the vaccine development of emerging and re-emerging viruses. CONCLUSION: Instead of handling live highly pathogenic viruses in a high biosafety level facility, using pseudovirus systems would speed up the process of vaccine development to provide community protection against emerging and re-emerging viral diseases with high pathogenicity.


Assuntos
Betacoronavirus/efeitos dos fármacos , Infecções por Coronavirus/tratamento farmacológico , Influenza Aviária/tratamento farmacológico , Pneumonia Viral/tratamento farmacológico , Vacinas Virais , Animais , Betacoronavirus/imunologia , Betacoronavirus/patogenicidade , Aves , COVID-19 , Vacinas contra COVID-19 , Infecções por Coronavirus/prevenção & controle , Desenvolvimento de Medicamentos/métodos , Humanos , Vírus da Influenza A/imunologia , Influenza Aviária/prevenção & controle , Influenza Aviária/virologia , Pandemias/prevenção & controle , Pneumonia Viral/prevenção & controle , SARS-CoV-2
2.
J Biomed Sci ; 27(1): 17, 2020 Jan 06.
Artigo em Inglês | MEDLINE | ID: mdl-31906961

RESUMO

BACKGROUND: Influenza A viruses cause epidemics/severe pandemics that pose a great global health threat. Among eight viral RNA segments, the multiple functions of nucleoprotein (NP) play important roles in viral replication and transcription. METHODS: To understand how NP contributes to the virus evolution, we analyzed the NP gene of H3N2 viruses in Taiwan and 14,220 NP sequences collected from Influenza Research Database. The identified genetic variations were further analyzed by mini-genome assay, virus growth assay, viral RNA and protein expression as well as ferret model to analyze their impacts on viral replication properties. RESULTS: The NP genetic analysis by Taiwan and global sequences showed similar evolution pattern that the NP backbones changed through time accompanied with specific residue substitutions from 1999 to 2018. Other than the conserved residues, fifteen sporadic substitutions were observed in which the 31R, 377G and 450S showed higher frequency. We found 31R and 450S decreased polymerase activity while the dominant residues (31 K and 450G) had higher activity. The 31 K and 450G showed better viral translation and replication in vitro and in vivo. CONCLUSIONS: These findings indicated variations identified in evolution have roles in modulating viral replication in vitro and in vivo. This study demonstrates that the interaction between variations of NP during virus evolution deserves future attention.


Assuntos
Evolução Molecular , Variação Genética , Vírus da Influenza A Subtipo H3N2/fisiologia , Biossíntese de Proteínas/genética , Proteínas de Ligação a RNA , Proteínas do Core Viral , Replicação Viral/genética , Células A549 , Animais , Cães , Humanos , Influenza Humana/epidemiologia , Influenza Humana/genética , Influenza Humana/metabolismo , Células Madin Darby de Rim Canino , Proteínas do Nucleocapsídeo , Proteínas de Ligação a RNA/biossíntese , Proteínas de Ligação a RNA/genética , Taiwan , Proteínas do Core Viral/biossíntese , Proteínas do Core Viral/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...